Consumer groups push back on CMS' proposed relaxation of MU requirements

An impressive group of consumer advocacy organizations have banded together to express concerns about proposed changes to the Meaningful Use program.

Organized by the Consumer Partnership for Health (CPeH) and the Consumer-Purchase Alliance on behalf of a long list of other organizations, the groups' comments on Meaningful Use express disappointment with the government's latest proposals. 

Specifically, the groups warned that the Centers for Medicare & Medicaid Services' (CMS) plan to reduce the requirements for healthcare providers would undermine efforts to make patients and family caregivers true and equal partners in improving health through shared information, understanding and decision-making. The letter was signed by 50 groups representing consumers, employers, seniors, underserved communities, patients, people with disabilities, labor, caregivers and others.

“What CMS is proposing is a dramatic, unwelcome and unjustified retreat from its commitment to promote patient and family engagement,” said Debra L. Ness, president of the National Partnership, which helps lead both CPeH and the C-P Alliance. “Delivery system reform cannot succeed without active engagement of patients and family caregivers, and online access is a critical tool for many. Simply offering, but not necessarily using, online access will not improve care and health; we must promote active engagement if we are to achieve the goals of delivery system reform. We urge CMS to keep the existing patient-engagement thresholds.”

“Empowering patients and their family caregivers with electronic access to and use of their health information is also a critical step toward interoperability throughout the health care system,” said Bill Kramer, co-chair of the C-P Alliance and executive director for National Health Policy at the Pacific Business Group on Health. “Interoperability will enable the efficient collection, sharing, and use of health information by patients, providers, purchasers, and other health system stakeholders to achieve the triple aim of better care, smarter spending, and healthier people.”

Read the complete comments.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.